Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-005752-10
    Sponsor's Protocol Code Number:AT-100/001
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:
    Date on which this record was first entered in the EudraCT database:2022-09-14
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-005752-10
    A.3Full title of the trial
    A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention with AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)
    Studio clinico di Fase Ib, Randomizzato, in cieco, per la definizione della dose, finalizzato alla valutazione del profilo di sicurezza e tollerabilità della somministrazione di AT-100 (rhSP-D) in neonati pretermine ad alto rischio di sviluppare la Displasia Broncopolmonare (BPD)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Clinical trial to assess the safety of the drug named AT-100 in preterm neonates at high risk for development of bronchopulmonary dysplasia
    Studio clinico per valutare la sicurezza del farmaco AT-100 in neonati prematuri ad alto rischio di sviluppare la displasia broncopolmonare
    A.3.2Name or abbreviated title of the trial where available
    NA
    NA
    A.4.1Sponsor's protocol code numberAT-100/001
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04662151
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAirway Therapeutics, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAirway Therapeutics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAirway Therapeutics, Inc.
    B.5.2Functional name of contact pointJanet Elkins
    B.5.3 Address:
    B.5.3.1Street Address1200 Johnson Ferry Rd., Suite #300
    B.5.3.2Town/ cityMarietta
    B.5.3.3Post codeGA 30068
    B.5.3.4CountryUnited States
    B.5.4Telephone number+14704864687
    B.5.6E-mailelkins@airwaytherapeutics.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/14/1262
    D.3 Description of the IMP
    D.3.1Product nameAT-100
    D.3.2Product code [na]
    D.3.4Pharmaceutical form Lyophilisate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPEndotracheopulmonary use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNProteina D surfattante umana ricombinante
    D.3.9.1CAS number 2245003-06-7
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB197494
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Bronchopulmonary Dysplasia (BPD)
    Displasia Broncopolmonare (BPD)
    E.1.1.1Medical condition in easily understood language
    Bronchopulmonary Dysplasia
    Displasia Broncopolmonare
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10006475
    E.1.2Term Bronchopulmonary dysplasia
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the recommended highest-tolerated and safest-tested dose that maximizes benefit-to-risk of AT-100 in preterm neonates born initially between GA 25 weeks and 28 6/7 weeks, then between GA 23 weeks and 28 6/7 weeks, who are at high risk for the development of BPD.
    Determinare la dose massima raccomandata più sicura e più tollerata che renda ottimale il rapporto rischio-beneficio di AT-100 in neonati prematuri nati inizialmente tra la 25° settimana e la 28° settimana più 6/7 giorni di età gestazionale (GA), che sono ad alto rischio di sviluppare la BPD.
    E.2.2Secondary objectives of the trial
    To evaluate preliminary efficacy parameters.
    Effettuare un’analisi preliminare dell’efficacia di AT-100.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Inpatient preterm neonates born between GA 25 to 28 6/7 weeks, inclusive, for the dose escalation cohorts; GA 23 to 28 6/7 weeks, inclusive, for the latter cohort receiving the highest-tolerated and safest tested dose.
    2. Intubated and on mechanical ventilation.
    3. Receiving at least 1 dose of standard-of-care-indicated surfactant treatment (Curosurf®) after birth, and able to receive the first dose of AT-100 or air-sham within 96 hours of birth given at any point after 15 minutes following any of the the subject's Curosurf® dose(s).
    4. Parent or legal guardian (as per local laws governing birth & neonate decision rights) is able to understand and sign a written informed consent form (ICF), which must be obtained prior to treatment and any study-related procedures.
    5. Parent or legal guardian is able to understand and sign a consent or authorization form, which shall permit the use, disclosure, and transfer of the subject's personal health information (e.g., in the USA, Health Information Portability and Accountability Act [HIPAA] Authorization form).
    6. Parent or legal guardian is willing and able to have neonate complete all trial procedures and successfully complete the trial.
    1. Neonati pretermine nati tra la 25° settimana di GA e la 28° settimana più 6/7 girni inclusa, per le coorti di aumento della dose; tra la 23° settimana di GA e la 28° settimana più 6/7 giorni inclusa, per l’ultima coorte che riceve la dose più alta e più sicura testata.
    2. Essere intubati e sottoposti e ventilazione meccanica.
    3. Ricevere almeno una dose di surfattante commerciale come da pratica clinica (Curosurf®) dopo la nascita e che sono in grado ricevere la prima dose di AT-100 o placebo sotto forma di somministrazione simulata di sola aria entro le 96 ore dalla nascita, somministrato in ogni momento una volta trascorsi 15 minuti da qualsiasi dose di Curosurf® assunta dal soggetto.
    4. Il genitore o il tutore legale (come previsto dalle normative locali che regolano la nascita i diritti di decisione del neonato), è in grado di comprendere e firmare un modulo di consenso informato scritto, che deve essere ottenuto prima del trattamento e di qualsiasi procedura relativa allo studio.
    5. Il genitore o il tutore legale è in grado di comprendere e firmare un modulo di consenso o di autorizzazione che consente l’utilizzo, la divulgazione e il trasferimento delle informazioni sanitarie personali del soggetto (ad es. negli Stati Uniti, il modulo di autorizzazione “Health Insurance Portability and Accountability Act [HIPAA]”).
    6. Il genitore o il tutore legale accetta ed è in grado di far completare al neonato tutte le procedure di sperimentazione e di completare con successo lo studio.
    E.4Principal exclusion criteria
    1. Weight at time of birth < 400 g or > 1,800 g.
    2. Major apparent congenital abnormalities impacting cardio and pulmonary function such as, but not limited to:
    a. congenital diaphragmatic hernia,
    b. congenital pulmonary airway malformation,
    c. omphalocele, or
    d. known or suspected cyanotic congenital heart disease (i.e., tetralogy
    of fallot, transposition of the great arteries, etc.).
    3. Active DNR (Do Not Resuscitate) order in place.
    4. Known pulmonary air leaks (e.g., pneumothorax or pneumomediastinum) at the time of AT-100 or air-sham administration.
    5. History of allergy or sensitivity to any surfactant or any component of the Investigational Product (AT-100).
    6. AT-100 or air-sham dosing was set to occur before DSMC recommendation to proceed to the next dose-escalation cohort.
    7. Use of minimally invasive surfactant administration techniques (e.g., LISA, MIST) or INSURE or if, in the opinion of the care team, the infant is very likely to be extubated shortly after receiving Curosurf.
    a. Subjects extubated and re-intubated after their Curosurf dose(s) are eligible, so long as the subject meets Inclusion#3.
    8. Birth mother:
    a. Has known active Hepatitis B, C, or E diagnosis.
    b. Has known illness or exposure that, in the judgement of the
    Investigator, is serious enough to induce an immune deficiency such as
    Human Immunodeficiency Virus (HIV) and/or is receiving
    chemotherapy.
    c. Has known active Sexually Transmitted Infection (STI) (i.e., Herpes Simplex Virus [HSV] with known active lesions; HIV; current Syphilis, Gonococcal, or Chlamydial infection that has not been treated)
    d. Has known Cytomegalovirus (CMV) active infection (not including CMV-carrier).
    e. Has known history or evidence of alcohol or drug abuse, with the exception of marijuana/marijuana-based products/THC, based on a positive maternal or infant drug screen as evidenced by the institution's standard-of-care practice.
    9. For the neonate, concurrent enrollment in an investigational drug, device, or treatment modulation trial that utilizes treatments outside of standard-of-care or participation in such a trial within the last 30 days (or 5 half-lives of an investigational product) prior to birth or up to Week 36 PMA.
    10. Any condition or situation which, in the Investigator's judgement, puts the mother or the neonate at significant risk, could confound the trial results, or may interfere
    significantly with the mother's or neonate's participation in the trial.
    11. Symptomatic and confirmed COVID-19 infection of the mother around the time of birth.
    1. Peso al momento della nascita <400 gr o >800 gr.
    2. Anomalie congenite gravi apparenti che hanno un impatto sulla funzione cardiaca e polmonare come, a titolo esemplificativo ma non esaustivo:
    a. ernia diaframmatica congenita,
    b. malformazione polmonare congenita,
    c. onfalocele, o
    d. cardiopatia cianotica congenita nota o sospetta (ad es. tetralogia di Fallot, trasposizione delle grandi arterie, ecc.)
    3. Ordine di non rianimare (DNR) in atto.
    4. Perdite d’aria polmonari note (es. pneumotorace o pneumomediastino) al momento della somministrazione dell’AT-100 o del placebo sotto forma di somministrazione simulata di sola aria.
    5. Anamnesi di allergia o sensibilità a qualsiasi surfattante o componente del prodotto in sperimentazione (AT-100).
    6. La somministrazione di AT-100 o di placebo sotto forma di somministrazione simulata di sola aria era stata programmata prima che il comitato per il monitoraggio dei dati e della sicurezza (Data Safety Monitoring Committee -
    DSMC) raccomandasse il passaggio alla coorte di dosaggio successiva.
    7. Uso di tecniche di somministrazione di surfattante minimamente invasive (ad es. LISA, MIST), o INSURE o se, a giudizio del team di studio, è molto probabile che il neonato venga estubato poco dopo aver ricevuto il Curosurf®:
    a. I soggetti estubati e reintubati dopo la somministrazione di Curosurf® possono essere arruolati, a condizione che il soggetto soddisfi il criterio di inclusione n. 3.
    8. La madre biologica:
    a. Ha una diagnosi nota e attiva di epatite B, C o E.
    b. Ha una malattia nota o un’esposizione che, a giudizio dello Sperimentatore, è abbastanza grave da indurre un’immunodeficienza come il virus dell’immunodeficienza umana (HIV) e/o sta ricevendo chemioterapia.
    c. Ha un’infezione sessualmente trasmissibile (IST) nota e attiva (es. virus herpes simplex [HSV] con lesioni attive note, AIDS, sifilide, infezione da gonococco o clamidia non trattata).
    d. Ha un’infezione nota e attiva da Citomegalovirus (CMV) nota (ad eccezione dei portatori di CMV).
    e. Ha una storia nota o prove di abuso di alcol o droghe, (ad eccezione di marijuana/prodotti a base di marijuana/THC,) sulla base di uno screening tossicologico positivo effettuato sulla madre o sul neonato, come evidenziato dalla pratica clinica dell’istituzione.
    9. Per il neonato, la partecipazione concomitante a un trial clinico per un farmaco sperimentale o un dispositivo, oppure a uno studio sulla modulazione del trattamento che utilizza prassi diverse dalla terapia standard o, ancora, la partecipazione a tale studio negli ultimi 30 giorni (o 5 emivite di un prodotto sperimentale) prima della nascita o fino alla 36 a settimana di PMA.
    10. Qualsiasi condizione o situazione che, a giudizio dello Sperimentatore, esponga la madre o il neonato a un rischio significativo, possa confondere i risultati della sperimentazione o possa interferire considerevolmente con la partecipazione della madre o del neonato alla sperimentazione.
    11. Infezione sintomatica e confermata da COVID-19 della madre nel periodo prossimo alla nascita.
    E.5 End points
    E.5.1Primary end point(s)
    Safety and tolerability of AT-100
    Sicurezza e tollerabilità di AT-100
    E.5.1.1Timepoint(s) of evaluation of this end point
    From time of initial AT-100 dosing until end of the study participation up to 36 Weeks Postmenstrual Age
    Dal momento della somministrazione iniziale di AT-100 alla fine della partecipazione allo studio, fino a 36 settimane di età postmestruale
    E.5.2Secondary end point(s)
    Time (days) on mechanical ventilation from birth to 36 weeks PMA; Incidence of BPD grade (0 to 3) or death; Overall survival; Mean %FiO 2; Proportion of subjects on mechanical ventilator modes; Mechanical ventilator peak inspiratory pressures (PIP); Mechanical ventilator positive end expiratory pressures (PEEP); Mechanical ventilator Mean Airway Pressure (MAP); Mechanical ventilator Tidal Volumes; Mechanical ventilator rates; Change from baseline in inflammation biomarkers; Incidence of pulmonary air leaks (e.g., pneumothorax, pneumomediastinum); Incidence of steroid use; Total cumulative steroids used; Incidence of pneumonia confirmed by X-ray; Incidence of blood culture positive infection; Survival following blood culture positive infection; Incidence of viral infection, as confirmed by culture or PCR (polymerase chain reaction); Survival following viral infection, as confirmed by culture or PCR; Incidence of Retinopathy of Prematurity (ROP); Incidence of Patent Ductus Arteriosus (PDA) requiring medical or surgical treatment; Incidence of Pulmonary Hypertension; Incidence of Necrotizing Enterocolitis (NEC); Incidence and severity of graded Intraventricular Hemorrhage (IVH); Incidence of surgical intervention for IVH; Incidence of Periventricular Leukomalacia; Number of days in hospital (any department); Incidence of BPD or death at Week 36 PMA; Exploratory endpoint: Inflammatory biomarker analysis (at specified timepoints through Week 36 PMA, see Schedule of Assessments)
    Tempo (giorni) trascorso sotto ventilazione meccanica dalla nascita alle 36° settimana di PMA; Incidenza del grado di BPD (da 0 a 3) o morte; Sopravvivenza complessiva; Percentuale media di FiO 2; Proporzione di soggetti sottoposti a ventilazione meccanica; Picco di pressione inspiratoria (PIP) del ventilatore meccanico; Pressione positiva di fine espirazione (PEEP) del ventilatore meccanico; Pressione arteriosa media (MAP) del ventilatore meccanico; Volume corrente del ventilatore meccanico; Frequenza respiratoria del ventilatore meccanico; Variazione dei biomarcatori infiammatori rispetto al valore basale; Incidenza di perdite d’aria polmonari (es. pneumotorace, pneumomediastino); Incidenza dell’uso di steroidi; Quantità cumulativa totale di steroidi utilizzati; Incidenza di polmonite confermata da raggi X; Incidenza di infezioni con emocoltura positiva; Sopravvivenza dopo infezione con emocoltura positiva; Incidenza di infezione virale confermata da coltura o PCR (reazione a catena della polimerasi); Sopravvivenza dopo infezione virale confermata da coltura o PCR; Incidenza di retinopatia del prematuro (ROP); Incidenza di dotto arterioso pervio (PDA) che richiede trattamento medico o chirurgico; Incidenza di ipertensione polmonare; Incidenza di enterocolite necrotizzante (NEC); Incidenza e gravità dell’emorragia intraventricolare (IVH) misurata; Incidenza di interventi chirurgici per IVH; Incidenza di leucomalacia periventricolare; Numero di giorni in ospedale (qualsiasi reparto); Indicidenza di BPD o di morte alla 36° settimana di PMA; Endopoint esploratorio: Analisi dei biomarcatori infiammatori (a intervalli specifici fino alla 36 a settimana di PMA, vedi “Schedula delle valutazioni”)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline through Week 36 Postmenstrual Age; Baseline
    Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di età post mestruale; Dalla visita basale alla 36 a settimana di e
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Tollerabilità
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Dose finding
    Determinazione della dose
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    terapia standard più somministrazione di sola aria (“air sham”)
    Standard-of-care plus air-sham intervention
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA17
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    France
    Spain
    Italy
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Yes
    F.1.1.2.1Number of subjects for this age range: 36
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    paediatric patients (neonates)
    Pazienti pediatrici (neonati)
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state5
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 18
    F.4.2.2In the whole clinical trial 36
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard of care
    Terapia standard
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-03-28
    N.Ethics Committee Opinion of the trial applicationWithdrawn
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-04-20
    P. End of Trial
    P.End of Trial Status
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 14:58:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA